Mr. Ali Hedayat reports

DRI HEALTHCARE COMMENTS ON VIRIDIAN'S FDA APPROVAL AND LAUNCH OF LUMVOA (VELIGROTUG-VVZE)

DRI Healthcare Trust today commented on Viridian Therapeutics Inc.'s recently announced approval by the United States Food and Drug Administration (FDA) of Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is an autoimmune inflammatory disorder of the orbit (eye socket) that affects numerous patients in the U.S. and can cause debilitating and disfiguring eye symptoms (for example, inflammation, proptosis and double-vision) with severe disease leading to vision loss.

DRI Healthcare is entitled to receive a tiered royalty on annual U.S. net sales of Viridian's TED franchise. In connection with the FDA approval of Lumvoa (veligrotug-vvze), DRI Healthcare will make a milestone payment of $75-million (U.S.) to Viridian pursuant to the terms of its existing royalty agreement with Viridian.

"We are pleased to see Viridian achieve FDA approval and launch Lumvoa (veligrotug-vvze) in the United States," said Ali Hedayat, chief executive officer of DRI Healthcare. "This milestone reinforces DRI Healthcare's strategy of allocating capital to differentiated therapies with meaningful clinical value, while seeking to generate attractive returns for our unitholders."

"Congratulations to the Viridian team on the approval of Lumvoa (veligrotug-vvze) which is poised to provide patients with TED a new treatment option with greater convenience. We look forward to seeing the continued progression of Viridian's second-generation TED product candidate, elegrobart. This product, if approved, could provide even greater convenience as the first true subcutaneous auto-injector for TED," said Navin Jacob, chief investment officer of DRI Healthcare.

About DRI Healthcare Trust

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since its founding in 1989, it has deployed more than $3.0-billion, acquiring more than 75 royalties on 50-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol DHT.UN and in U.S. dollars under the symbol DHT.U.

We seek Safe Harbor.